IPO priced at the top of the range, indicating strong demand. The company is a pre-revenue clinical-stage biotech with Phase 1 data for LCA-0061 showing 96% mean IgE reduction. Key catalysts to watch: additional Phase 1 data for LCA-0061 and LCA-0321 expected in 2027, and IND clearance for LCA-0062. The IPO provides a ~$290M cash runway into 2H2029, but the company will need substantial additional capital to fund Phase 3 trials and commercialization.
Executive Summary
Lycia Therapeutics priced its IPO at $18.00 per share, selling 17,640,000 shares for total gross proceeds of $317.5 million. The offering is now complete and shares will begin trading on the Nasdaq Global Select Market under the ticker LYCA. Net proceeds of approximately $290.7 million will fund clinical development of its LYTAC platform programs (LCA-0061, LCA-0062, LCA-0321) through Phase 2 trials and for working capital.
Key Financial Metrics
Key Facts
- IPO priced at $18.00 per share, at the top of the $16.00-$18.00 range indicated in the preliminary prospectus
- 17,640,000 shares offered (base); underwriters have 30-day option for an additional 2,646,000 shares
- Total gross proceeds: $317,520,000; net proceeds to company before expenses: $295,293,600
- Underwriters: Jefferies, TD Cowen, Evercore ISI, Guggenheim Securities (joint book-running managers); LifeSci Capital (passive book-runner)
- Underwriting discount: $1.26 per share ($22,226,400 total)
- Shares expected to deliver on or about October 26, 2026
- Pro forma as-adjusted cash position: $439.4 million; cash runway into second half of 2029
- Proceeds allocated: ~$80M to LCA-0061 Phase 2, ~$70M to LCA-0062 Phase 2, ~$90M to LCA-0321 Phase 2, remainder for pipeline and working capital
- No public market existed prior to this offering; no lock-up period explicitly stated in the filing document
Financial Impact
IPO raised $317.5M gross; net proceeds ~$290.7M after underwriting discounts and estimated expenses. Proceeds extend cash runway into second half of 2029.
Risk Factors
- Pre-revenue, pre-revenue clinical-stage biotech with no approved products and no products approved for commercial sale
- Accumulated deficit of $136.8M as of June 30, 2026; net loss of $19.2M in H1 2026
- Dependence on LYTAC platform; no LYTAC-based therapy has been approved by FDA
- Will require substantial additional capital beyond current runway to complete Phase 3 trials and commercialization
- Risk of clinical trial failure in Phase 1 trials for LCA-0061 and LCA-0321
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B4 Filing (Primary) | 0001628280-26-067048 |
| Document: 0001628280-26-067048-index-headers.html | 0001628280-26-067048 |
| Document: 0001628280-26-067048-index.html | 0001628280-26-067048 |
| Document: 0001628280-26-067048.txt | 0001628280-26-067048 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | Press Release | $28.85 | awaiting T+1 | — | $28.85 (+0.00%) |
Oct 23, 2026 3d ago | 424B4 | $28.11 | awaiting T+1 | — | $28.85 (+2.63%) |
Oct 23, 2026 4d ago | EFFECT | $30.00 $28.85 | ▼ −3.83% | ▼ −4.54% | $28.85 (−3.83%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers